The case for & against
Bull & Bear analysis
Bearish
Liminal BioSciences (LMNL) was a biotechnology company focused on discovering and developing innovative therapeutics for various diseases. The company was particularly known for its efforts in the development of plasma-derived therapeutic products. With its shares having recently moved to private ownership following a transaction with Structured Alpha LP, LMNL ceased its role as a public entity. The move has effectively taken it out of the spotlight for ongoing public financial reporting and market performance evaluation, creating a lack of visibility in the market.
Bull says
- ↑$8.50 per‐share acquisition represents clear premium to pre‐deal levels
- ↑Delisting from Nasdaq cuts reporting costs and boosts operational flexibility
- ↑Structured Alpha LP ownership may accelerate plasma‐derived therapy R&D
- ↑Biotech sector growth and supportive regulations underpin pipeline upside
- ↑Private structure allows long‐term project focus without quarterly pressure
- ↑Strategic alignment with private owner can streamline decision‐making
Bear says
- ↓Transition to private ownership ends Nasdaq reporting, limiting transparency
- ↓Structured Alpha LP’s strategic priorities remain unclear, heightening execution risk
- ↓Absence of public metrics obscures operational health and funding needs
- ↓Post‐deal delisting may constrain access to future capital and partnerships
- ↓Competition from Grifols, Takeda and peers could challenge niche moat
- ↓Macro headwinds or biotech setbacks could further pressure returns